We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
(-4.5%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26
Avg Time Held Equity + Options
10
quarters
Top 10 Avg Time Held Equity + Options
6.8
quarters
Top 20 Avg Time Held Equity + Options
6.6
quarters
Avg Time Held Equity only
10.6
quarters
Top 10 Avg Time Held Equity only
6.8
quarters
Top 20 Avg Time Held Equity only
6.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caris Life Sciences
CAI
|
+$81.8M |
| 2 |
UnitedHealth
UNH
|
+$51.6M |
| 3 |
Roivant Sciences
ROIV
|
+$30.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$23.2M |
| 5 |
Jade Biosciences
JBIO
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$56.9M |
| 4 |
SpringWorks Therapeutics
SWTX
|
+$41.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.99% |
| 2 | Miscellaneous | 1.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
MBX Biosciences
MBX
$2.4B
| $45.7M | 1.14% |
4,002,887
| – | – |
2024 Q3
3 quarters
|
|
27
Axsome Therapeutics
AXSM
$8.2B
| $44.7M | 1.12% |
427,900
+41,200
| +11% | +$4.36M |
2025 Q1
1 quarter
|
|
28
Compass Therapeutics
CMPX
$155M
| $39.6M | 0.99% |
15,219,994
-7,142,856
| -32% | -$14.7M |
2021 Q4
14 quarters
|
|
29
Cytokinetics
CYTK
$8.62B
| $35.6M | 0.89% |
1,077,000
-432,205
| -29% | -$15M |
2024 Q1
5 quarters
|
|
30
DELISTED
Crinetics Pharmaceuticals
CRNX
| $33M | 0.83% |
1,149,000
+150,000
| +15% | +$4.63M |
2018 Q3
27 quarters
|
|
31
DELISTED
Exact Sciences
EXAS
| $32.3M | 0.81% |
607,316
-72,500
| -11% | -$3.68M |
2024 Q1
5 quarters
|
|
32
DELISTED
Third Harmonic Bio
THRD
| $31.4M | 0.78% |
5,779,071
| – | – |
2022 Q3
11 quarters
|
|
|
33
Roivant Sciences
ROIV
$24.2B
| $31.3M | 0.78% |
+2,779,427
| New | +$30.1M |
2025 Q2
0 quarters
|
|
34
Xenon Pharmaceuticals
XENE
$3.36B
| $29.7M | 0.74% |
947,877
| – | – |
2016 Q3
35 quarters
|
|
35
Neuropace
NPCE
$440M
| $29.1M | 0.73% |
2,614,184
-792,151
| -23% | -$9.9M |
2021 Q2
16 quarters
|
|
36
Corvus Pharmaceuticals
CRVS
$796M
| $28.7M | 0.72% |
7,165,006
+221,352
| +3% | +$805K |
2016 Q1
37 quarters
|
|
37
DELISTED
Terns Pharmaceuticals
TERN
| $28.2M | 0.7% |
7,562,971
| – | – |
2021 Q1
17 quarters
|
|
38
Janux Therapeutics
JANX
$1.06B
| $28M | 0.7% |
1,210,300
+451,734
| +60% | +$11.9M |
2021 Q2
16 quarters
|
|
39
DELISTED
Apellis Pharmaceuticals
APLS
| $25.7M | 0.64% |
1,482,300
+50,000
| +3% | +$926K |
2025 Q1
1 quarter
|
|
40
Structure Therapeutics
GPCR
$1.6B
| $24.9M | 0.62% |
1,199,300
+547,272
| +84% | +$12M |
2024 Q2
4 quarters
|
|
41
DELISTED
scPharmaceuticals
SCPH
| $23.1M | 0.58% |
6,059,528
| – | – |
2017 Q4
30 quarters
|
|
42
CytomX Therapeutics
CTMX
$514M
| $19.2M | 0.48% |
+8,461,500
| New | +$13.6M |
2025 Q2
0 quarters
|
|
|
43
Thermo Fisher Scientific
TMO
$246B
| $18.9M | 0.47% |
46,500
-82,500
| -64% | -$34.5M |
2013 Q2
48 quarters
|
|
44
Agios Pharmaceuticals
AGIO
$1.81B
| $18.6M | 0.46% |
557,900
+232,400
| +71% | +$7.04M |
2024 Q4
2 quarters
|
|
45
Trevi Therapeutics
TRVI
$1.77B
| $18.1M | 0.45% |
3,308,400
+2,188,400
| +195% | +$13.6M |
2025 Q1
1 quarter
|
|
46
ADC Therapeutics
ADCT
$216M
| $15.8M | 0.4% |
5,907,351
-61,100
| -1% | -$129K |
2024 Q2
4 quarters
|
|
47
Rhythm Pharmaceuticals
RYTM
$6B
| $15.7M | 0.39% |
248,512
-131,488
| -35% | -$8.05M |
2023 Q3
7 quarters
|
|
|
48
CALL
UnitedHealth
UNH
$339B
| $15.6M | 0.39% |
+50,000
| New | +$19.1M |
2025 Q2
0 quarters
|
|
49
DELISTED
Forte Biosciences
FBRX
| $15.5M | 0.39% |
1,196,955
+603,867
| +102% | +$5.2M |
2024 Q4
2 quarters
|
|
50
Cullinan Oncology
CGEM
$917M
| $14.5M | 0.36% |
1,923,855
| – | – |
2021 Q1
17 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2025 Portfolio in Review
As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.
- OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
- OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
- OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
- OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
- OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
- OrbiMed opened 18 new positions and closed 26 in Q2 2025.
- OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.
Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.